Plain-English translation of NCT07340853 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called anti-BCMA CAR-T cells for patients with multiple myeloma that has come back or stopped responding to other drugs. The treatment works by taking your own immune cells, modifying them in a lab to fight your cancer, and putting them back into your body. Researchers want to see if this medication is safe and whether it helps patients live longer.
Multiple myeloma is a serious blood cancer, and many patients eventually run out of treatment options because their cancer becomes resistant to standard drugs. This trial exists to find a new way to help patients whose disease has stopped responding to three or more previous treatments, including newer therapies.
If you join, you will first undergo a procedure called leukapheresis, where doctors collect some of your immune cells through a needle in your arm. Your cells are then sent to a lab to be genetically modified. While that happens, you will receive chemotherapy drugs to prepare your body. About a week later, you will receive an infusion of your modified cells back into your body. After that, you will have follow-up visits and blood tests at 30 days, 60 days, and beyond to monitor how you respond and check for any side effects.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States